Technical Analysis for ZYME - Zymeworks Inc.

Grade Last Price % Change Price Change
F 28.59 7.40% 1.97
ZYME closed up 7.4 percent on Friday, May 14, 2021, on 81 percent of normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Down
Historical ZYME trend table...

Date Alert Name Type % Chg
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
Oversold Stochastic Weakness 0.00%
Outside Day Range Expansion 7.40%
Down 3 Days in a Row Weakness 7.40%
Down 4 Days in a Row Weakness 7.40%
Oversold Stochastic Weakness 7.40%
MACD Bearish Signal Line Cross Bearish 3.66%
Stochastic Reached Oversold Weakness 3.66%
Inside Day Range Contraction 3.66%
Down 3 Days in a Row Weakness 3.66%
Older End-of-Day Signals for ZYME ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Zymeworks Inc. Description

Zymeworks Inc is a Canada-based clinical-stage biopharmaceutical company. The Company focuses on the discovery, development and commercialization of multifunctional biotherapeutics. The Company's ZymeCAD platform is for protein modeling and structure-guided protein engineering. The Company's platforms include Azymetric Platform, AlbuCORE Platform, EFECT Platform and Zymelink Conjugation Platform + Cytotoxins. The Company's lead product candidate, ZW25, is a bispecific antibody, which is being evaluated in an adaptive Phase I clinical trial. Its ZW33 is a bi-specific antibody that delivers a cytotoxic payload to cancers cells by binding to different epitopes (bi-paratopic targeting) of the overexpressed HER2 protein. It focuses on developing a pipeline of preclinical product candidates and discovery-stage programs in immuno-oncology and other therapeutic areas. It analyzes protein characteristics to develop the scope of protein engineering to tackle biological systems.


Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Immunology Immune System Cancers Monoclonal Antibodies Cancer Immunotherapy Antibody Her2 Toxins Sutro Biopharma Glycoproteins Biological Systems Bispecific Monoclonal Antibody Protein Engineering

Is ZYME a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 59.03
52 Week Low 24.82
Average Volume 431,763
200-Day Moving Average 39.55
50-Day Moving Average 30.99
20-Day Moving Average 29.18
10-Day Moving Average 29.04
Average True Range 1.90
ADX 29.72
+DI 15.49
-DI 29.03
Chandelier Exit (Long, 3 ATRs ) 27.99
Chandelier Exit (Short, 3 ATRs ) 30.51
Upper Bollinger Band 32.88
Lower Bollinger Band 25.48
Percent B (%b) 0.42
BandWidth 25.35
MACD Line -0.84
MACD Signal Line -0.72
MACD Histogram -0.1201
Fundamentals Value
Market Cap 1.3 Billion
Num Shares 45.6 Million
EPS -1.63
Price-to-Earnings (P/E) Ratio -17.54
Price-to-Sales 105.44
Price-to-Book 5.79
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 32.12
Resistance 3 (R3) 31.88 30.47 31.53
Resistance 2 (R2) 30.47 29.57 30.59 31.33
Resistance 1 (R1) 29.53 29.02 30.00 29.77 31.14
Pivot Point 28.12 28.12 28.36 28.24 28.12
Support 1 (S1) 27.18 27.22 27.65 27.42 26.04
Support 2 (S2) 25.77 26.67 25.89 25.85
Support 3 (S3) 24.83 25.77 25.65
Support 4 (S4) 25.07